학술논문
New indolicidin analogues with potent antibacterial activity.
Document Type
Article
Author
Source
Subject
*TRYPTOPHAN
*PEPTIDES
*CYTOPLASMIC granules
*ERYTHROCYTES
*ORGANELLES
*CHEMISTRY
*BIOCHEMISTRY
*
*
*
*
*
*
Language
ISSN
1397-002X
Abstract
Indolicidin is a 13-residue antimicrobial peptide amide, ILPWKWPWWPWRR-NH2, isolated from the cytoplasmic granules of bovine neutrophils. Indolicidin is active against a wide range of microorganisms and has also been shown to be haemolytic and cytotoxic towards erythrocytes and human T lymphocytes. The aim of the present paper is two-fold. First, we examine the importance of tryptophan in the antibacterial activity of indolicidin. We prepared five peptide analogues with the format ILPXKXPXXPXRR-NH2 in which Trp-residues 4,6,8,9,11 were replaced in all positions with X = a single non-natural building block;N-substituted glycine residue or nonproteinogenic amino acid. The analogues were tested for antibacterial activity against bothStaphylococcus aureusAmerican type culture collection (ATCC) 25923 andEscherichia coliATCC 25922. We found that tryptophan is not essential in the antibacterial activity of indolicidin, and even more active analogues were obtained by replacing tryptophan with non-natural aromatic amino acids. Using this knowledge, we then investigated a new principle for improving the antibacterial activity of small peptides. Our approach involves changing the hydrophobicity of the peptide by modifying the N-terminus with a hydrophobic non-natural building block. We prepared 22 analogues of indolicidin and [Phe4,6,8,9,11] indolicidin, 11 of each, carrying a hydrophobic non-natural building block attached to the N-terminus. Several active antibacterial analogues were identified. Finally, the cytotoxicity of the analogues against sheep erythrocytes was assessed in a haemolytic activity assay. The results presented here suggest that modified analogues of antibacterial peptides, containing non-natural building blocks, are promising lead structures for developing future therapeutics. [ABSTRACT FROM AUTHOR]